Perfluorohexyloctane

Perfluorohexyloctane
Clinical data
Trade names	Miebo
Other names	NOV03; 1-(perfluorohexyl)octane
License data	US DailyMed: Perfluorohexyloctane;
Routes of; administration	Eye drops
ATC code	None;
Legal status
Legal status	US: ℞-only[1];
Identifiers
	IUPAC name 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane;
CAS Number	133331-77-8;
PubChem CID	10477896;
DrugBank	DB17823;
ChemSpider	8653305;
UNII	7VYX4ELWQM;
KEGG	D12604;
CompTox Dashboard (EPA)	DTXSID20440585 ;
Chemical and physical data
Formula	C14H17F13
Molar mass	432.269 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F;
	InChI InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3; Key:WRYIIOKOQSICTB-UHFFFAOYSA-N;

Perfluorohexyloctane, sold under the brand name Miebo is a medication used for the treatment of dry eye disease.[1] It is a semifluorinated alkane.[1]

Perfluorohexyloctane was approved for medical use in the United States in May 2023.[1][2]

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[1]

References

"Miebo- perfluorohexyloctane solution". DailyMed. 18 May 2023. Retrieved 8 June 2023.
"Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Miebo_FDA_label-1] "Miebo- perfluorohexyloctane solution". DailyMed. 18 May 2023. Retrieved 8 June 2023.

[2] "Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.